---
figid: PMC7400772__ol-20-03-2075-g00
figtitle: Immune evasion in EC
organisms:
- NA
pmcid: PMC7400772
filename: ol-20-03-2075-g00.jpg
figlink: pmc/articles/PMC7400772/figure/f1-ol-0-0-11774/
number: F1
caption: 'Mechanisms of immune evasion in EC. The mechanisms mainly include the inhibition
  of T-lymphocyte activity by the AKT/NF-κB/IκB/COX-2 signaling pathway, VISTA and
  TAMs; the inhibition of NK cell activity by IDO and PIBF; gene mutation (JAK1, MUC16
  and NLRC5); the promotion of EC cell sensitivity to estrogen by IL4/IL13-induced
  CD68+CD163+ macrophages; and the promotion of PD-L1 protein expression by estrogen.
  CTL, cytotoxic T lymphocyte; EC, endometrial cancer; ER-α: estrogen receptor-α;
  JAK1, Janus kinase 1; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; MSI, microsatellite
  instability; MHC, major histocompatibility complex; NK, natural killer; NLRC5, NLR
  family, caspase recruitment domain-containing 5; PD-1, programmed cell death-1;
  PD-L1, PD-1 ligand 1; Treg, regulatory T cell; Th, T helper cell; IFN, interferon;
  TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; NF-κB, nuclear
  factor-κB; IκB, inhibitor of κB; COX-2, cyclooxygenase-2; MUC16, mucin 16; TIL,
  tumor-infiltrating lymphocyte; OS, overall survival; PI3K, phosphoinositide 3-kinase;
  TAM, tumor-associated macrophage; VISTA, V-set immunoregulatory receptor; LMP-2,
  latent membrane protein 2; TAP-1, Transporter-1, ATP-binding cassette subfamily
  B member; PIBF, progesterone-induced blocking factor.'
papertitle: 'Immune disorder in endometrial cancer: Immunosuppressive microenvironment,
  mechanisms of immune evasion and immunotherapy.'
reftext: Lei Zhan, et al. Oncol Lett. 2020 Sep;20(3):2075-2090.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9695524
figid_alias: PMC7400772__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7400772__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7400772__ol-20-03-2075-g00.html
  '@type': Dataset
  description: 'Mechanisms of immune evasion in EC. The mechanisms mainly include
    the inhibition of T-lymphocyte activity by the AKT/NF-κB/IκB/COX-2 signaling pathway,
    VISTA and TAMs; the inhibition of NK cell activity by IDO and PIBF; gene mutation
    (JAK1, MUC16 and NLRC5); the promotion of EC cell sensitivity to estrogen by IL4/IL13-induced
    CD68+CD163+ macrophages; and the promotion of PD-L1 protein expression by estrogen.
    CTL, cytotoxic T lymphocyte; EC, endometrial cancer; ER-α: estrogen receptor-α;
    JAK1, Janus kinase 1; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; MSI,
    microsatellite instability; MHC, major histocompatibility complex; NK, natural
    killer; NLRC5, NLR family, caspase recruitment domain-containing 5; PD-1, programmed
    cell death-1; PD-L1, PD-1 ligand 1; Treg, regulatory T cell; Th, T helper cell;
    IFN, interferon; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α;
    NF-κB, nuclear factor-κB; IκB, inhibitor of κB; COX-2, cyclooxygenase-2; MUC16,
    mucin 16; TIL, tumor-infiltrating lymphocyte; OS, overall survival; PI3K, phosphoinositide
    3-kinase; TAM, tumor-associated macrophage; VISTA, V-set immunoregulatory receptor;
    LMP-2, latent membrane protein 2; TAP-1, Transporter-1, ATP-binding cassette subfamily
    B member; PIBF, progesterone-induced blocking factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PSMB9
  - TAP1
  - SEC14L2
  - NFKB1
  - CD8A
  - CD8B
  - VSIR
  - AKT1
  - AKT2
  - AKT3
  - IL12A
  - IL12B
  - CCL22
  - IL10
  - MUC16
  - NLRC5
  - HLA-C
  - IH
  - IDO1
  - IL13
  - IL4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IL17A
  - CD274
  - NO2
  - Estrogen
  - Estradiol
  - estrogen
  - Cytotoxic
---
